BioLife Solutions, Inc.
Financials
Valuation Metrics
BioLife Solutions, Inc.'s Market Cap is $1.57B. At end of 2025 it was $1.15B. Ranked #2217 of 3,112 in US market (top 71%), #877 of 1,445 on NASDAQ (top 61%), #131 of 206 in Health Care Equipment & Services (top 64%) by Market Cap.
Investment Metrics(as of 2026-08-03)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | $1.57B | US#2,217/3,112 Sec#131/206 |
| Revenue | $100M | US#2,778/3,112 Sec#189/206 |
| Net Income | $-10M | US—/3,112 Sec—/206 |
| Total Assets | $401M | US#2,827/3,112 Sec#169/206 |
| Net Assets | $372M | US#2,445/3,112 Sec#134/206 |
| Employees | 155 | US#1,421/3,112 Sec#110/206 |
| Value | ||
| P/B | 4.22x | US#2,026/3,112 Sec#127/206 |
| P/S | 15.74x | US#2,771/3,112 Sec#198/206 |
| FCF Yield | -0.11% | US—/3,112 Sec—/206 |
| Profitability | ||
| ROE | -2.82% | US#2,257/3,112 Sec#122/206 |
| ROA | -2.62% | US#2,415/3,112 Sec#131/206 |
| Op. Margin | -10.91% | US#2,639/3,112 Sec#162/206 |
| Revenue Growth | 14.87% | US#974/3,112 Sec#65/206 |
| Financial Health | ||
| Debt Ratio | 7.70% | US#75/3,112 Sec#4/206 |
| Total Debt | $15M | US#2,740/3,112 Sec#178/206 |
| FCF | $-2M | US#2,281/3,112 Sec#148/206 |
| Cash | $23M | US#2,836/3,112 Sec#190/206 |
| Current Ratio | 7.30x | US#325/3,112 Sec#20/206 |
| Dividend | ||
| Div. Yield | 0.00% | US—/3,112 Sec—/206 |
| Payout Ratio | 0.00% | US—/3,112 Sec—/206 |
| Performance | ||
| 1Y Return | 54.49% | US#683/3,112 Sec#52/206 |
| 1M Return | 14.37% | US#311/3,112 Sec#30/206 |
| From 52W High | -2.99% | US#337/3,112 Sec#19/206 |
| 1Y MDD | -36.96% | US#1,801/3,112 Sec#92/206 |
| Trading | ||
| Volume | 572,087 shares | US#1,959/3,112 Sec#144/206 |
| Trading Value | $18M | US#2,016/3,112 Sec#136/206 |
| Per Share | ||
| EPS | $-0.38 | US—/3,112 Sec—/206 |
| BPS | $7.72 | US#1,965/3,112 Sec#116/206 |
Company Info
BioLife Solutions, Inc. develops, manufactures, and markets bioproduction products and services for the cell and gene therapy (CGT) industry in the United States, Europe, the Middle East, Africa, and internationally. The company's products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies. It offers proprietary biopreservation media products, including HypoThermosol FRS and CryoStor Freeze Media that are formulated to mitigate preservation-induced, delayed-onset cell damage and death; bioproduction products, such as human platelet lysates for cell expansion and CellSeal closed system vials that are used in CGT; CryoCase cryo-compatible transparent rigid containers for closed-system fill and retrieval, and automated cell processing machines; and the ThawSTAR line include automated thawing devices for frozen cell and gene therapies packaged in cryovials and cryobags. The company also provides evo shipping containers that are cloud-connected passive storage and transport containers for temperature-sensitive biologics and pharmaceuticals. It markets and sells its products directly, as well as through third party distributors. The company was incorporated in 1987 and is headquartered in Bothell, Washington.